



Dr. Larry Hsu is currently the Co-Founder, Chairman & CEO of Lifemax Healthcare International Corporation with primary focus on developing new drugs in the therapeutic areas of CNS and fibrosis. Lifemax Healthcare International Corporation was founded in later 2014 with two wholly-owned subsidiaries: Lifemax Laboratories, Inc. in U.S. and Lifemax Biotechnology, Inc. in Taiwan. It also has a majority-owned subsidiary, SquaMax Pharmaceuticals, which focuses its effort on developing a special drug delivery technology.

Prior to Lifemax, Dr. Hsu was the President and CEO of Impax Laboratories, a Nasdaq-listed specialty pharmaceutical company co-founded by him and a partner. Impax's business objective is applying its formulation, clinical development expertise and drug delivery technology to the development, manufacturing and distribution of controlled-release and specialty generics and branded prescription drugs. In the 18 years of its history, Impax Laboratories grew to a company with more than 1000 employees and a market cap of almost \$3 billion USD. Dr. Hsu retired from Impax in April 2014.

Dr. Hsu received his Ph.D. degree in Pharmaceutics from University of Michigan. He worked at Abbott laboratories for 15 years. During the last four years at Abbott, Dr. Hsu was the Director of Product Development in charge of worldwide product development, process engineering, clinical supplies manufacturing and production technical support of all dosage forms. Dr. Hsu received his B.S. degree in Pharmacy from National Taiwan University.